✅ACR 2025 guideline for management of extra renal Lupus 💊Steroid to be tapered with target < 5 mg/d by 6 months 👉👉GULP trial - no difference in relapse rate if pred >5 mg/d or pred <5 mg/d #ACR2025 #ACRheum #ACRambassador #MedTwitter

𝗣𝗹𝗮𝘀𝗺𝗮-𝗖𝗲𝗹𝗹 𝗗𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀. Plasma-cell disorders are a spectrum of conditions defined by a clonal plasma-cell population that produces a monoclonal protein that can be detected in the blood, urine, or both. Plasma-cell disorders range from asymptomatic

#ACR25 Abstr#641 Phase 1/2 CASTLE Basket Trial fully recruited N=24 (10 SLE, 9 SSc, 5 IIM). Short-term data of autologous CD19-CAR T Zorpocabtagene-autoleucel/MB19.1: - 22/24 high degree efficacy - no relapse - no high grade CRS/ICANS *Need larger Phase prior approval @RheumNow

Read this paper to know how to 'actually' read a paper! I've highlighted the key points -> now this 10 min read of 3-pass apprach will change your paper reading technique for good! 𝗞𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀: — First Pass (5-10 minutes) Quick scan for bird's-eye view — Second

SELECT-GCA (upadacitinib in GCA for 52w) we hoped it might have ongoing effect post-cessation Do we need to continue upa? Extension data (second year) flare survival curves are clear: continuing upa far outperforms placebo It seems >2y toci/upa for GCA #ACR25 ABST0776 @RheumNow

Useful list

Had just this case among my consults this week! Pterygium nails”, a classic finding in Lichen Planus with V-shaped distal splitting and ridging

Friday, OCT 17, the FDA approved #obinutuzumab #Gazyva for the treatment of #SLE #lupus nephritis when used with other standard therapies! Our patients now have even more hope. Complete renal responses were significantly higher than placebo with standard therapies. Studies

New content online: DADA2 as an autosomal dominant disease

Clinicians can enhance patient understanding by using numerical data instead of verbal probabilities, consistent denominators, absolute risk comparisons, and clear context for unfamiliar data types. https://t.co/dcOmkNwtlS

70% of cocaine is adulterated with levamisole. Drug test all patients with vasculitis/suspected vasculitis. - Dr Peter Merkel #CCRW25

NEW COMMENT—Targeting B-cell activation to tackle both patient-reported and systemic disease outcomes in Sjögren's disease https://t.co/ksHKDfYMSg

Daratumumab targeting CD38 and pan-JAK inhibitor eg baricitinib/ tofacitinib maybe emerging therapies for #MAS #aplar2025

Case study of sick MAS in sJIA used 12x pulses (1gx12 goodness!) oral CyA 5mg/kg then switch to IV CyA aiming for >800ng/ml, plus ultrafiltration. Just showed how sick/ desperate the treating Dr. lucky we now have Emapalumab #APLAR2025

Cxcl9 as surrogate for IFNg, IL-18, CD38+ CD8 lymphocytes are novel markers of #MAS, reflecting the activation of inflammasome, and T cell activation. #APLAR2025

Dynamic time course of lab parameters from onset of #MAS to full blown disease. Note ferritin rise is quite late. #APLAR2025

Proud to share @ZhiLim8's latest review on promising new treatments for #Sjogrens! 🧬 How engineered regulatory T cell therapies could help rebalance the immune system and bring relief to patients? @OoiLabs @alberta_hoi @MonashCID @SCSMonash @MonashHealth https://t.co/2QoJYFbY2L

lol. such a legend. Dr. Glaucomflecken Explains: Obinutuzumab in Lupus Nephritis (REGENCY) https://t.co/IqN5zJZQW5 via @YouTube

1⃣‘Sjögren disease’ should replace ‘Sjögren syndrome’ 2⃣Acronym = SjD 3⃣‘Associated’ should be used in lieu of ‘secondary’ 4⃣ SjD = preferred terminology in clinical diagnosis 5⃣Differentiation btw primary & associated recommended for scientific studies https://t.co/0f2iIZf37T

Wonderful paper for all levels of clinicians. Improving Patients’ Treatment Expectations